Cochrane | Trusted evidence. Informed decisions. Better health.
Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health.
What are the benefits and risks of vaccines for preventing COVID …
Dec 7, 2022 · Key messages – Most vaccines reduce, or probably reduce, the number of people who get COVID-19 disease and severe COVID-19 disease. – Many vaccines likely increase number of people experiencing events such as fever or headache compared to placebo (sham vaccine that contains no medicine but looks identical to the vaccine being tested).
Which long-acting inhalers are the most effective and safest
Long-acting bronchodilators such as long-acting β-agonist (LABA), long-acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations have been used in people with moderate to severe chronic obstructive pulmonary disease (COPD) to control symptoms such as dyspnoea and cough, and prevent exacerbations.
Duloxetine for treating painful neuropathy, chronic pain or
We identified 18 trials, which included 6407 participants. We found 12 of these studies in the literature search for this update. Eight studies included a total of 2728 participants with painful diabetic neuropathy and six studies involved 2249 participants with fibromyalgia.
About us - Cochrane
Cochrane is an international network with headquarters in the UK, a registered not-for-profit organization, and a member of the UK National Council for Voluntary Organizations.Cochrane produces systematic reviews, published in the Cochrane Library, to help people make informed health decisions.. Cochrane is for anyone interested in using high-quality information to make health decisions.
What are the benefits and risks of hypertonic saline solution via ...
Key messages. Compared to nebulised normal saline, nebulised hypertonic saline may reduce hospital stay by almost 10 hours for infants admitted with acute bronchiolitis; may improve 'clinical severity scores', which are used by doctors to assess disease severity; and may reduce the risk of hospitalisation by 13% amongst children treated as outpatients or in the emergency department.
Ivermectin for preventing and treating COVID-19 - Cochrane
We assessed RCTs for bias, using the Cochrane RoB 2 tool. We used GRADE to rate the certainty of evidence for outcomes in the following settings and populations: 1) to treat inpatients with moderate-to-severe COVID-19, 2) to treat outpatients with mild COVID-19 (outcomes: mortality, clinical worsening or improvement, (serious) adverse events, quality of life, and viral clearance), and 3) to ...
What are the benefits and risks of beds, mattresses and
Aug 16, 2021 · The overview presents a lot of data from randomised controlled trials and contains an advanced analysis called 'network meta-analysis'. The analysis allows comparisons of all types of support surfaces for preventing or treating pressure ulcers.
Does a strategy of extended-duration blood thinners for
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialized Register, CENTRAL, MEDLINE, Embase, CINAHL and Web of Science databases, as well as the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers up to 27 March 2023.
Blood pressure targets for older adults with high blood pressure
When comparing a higher BP target, in the range of < 150 to 160/95 to 105 mmHg, to a lower BP target of 140/90 or lower, over two to four years of follow-up, there is high-certainty evidence that the lower BP target reduces stroke, and moderate-certainty evidence that the lower BP target likely reduces serious cardiovascular events.